Evogene
EVGN · NASDAQ
$0.3716+$0.0036 (+0.98%)TodayMarket closed ·
Prev close $0.368
About EVGN
- Employees
- 142
- Headquarters
- Rehovot, Central(HaMerkaz)
- Listed
- Jun 11, 2007
- Sector
- Health Care
- Industry
- Biotechnology
- Website
- evogene.com
Leadership
| Name | Title | Since |
|---|---|---|
| Nir Nimrodi | — | 2025 |
| Ofer Haviv | — | 2002 |
| Dorit Kreiner | — | — |
| Brian Ember | — | — |
| Elran Haber | — | — |
| Arnon Heyman | — | — |
| Mark Kapel | — | — |
| Sassi Masliah | — | — |
| Nir Arbel | — | — |
| Dan Falk | — | — |
| Sarit Firon | — | — |
| Ziv Kop | — | — |
| Adrian Percy | — | — |
| Leon Recanati | — | — |
| Oded Shoseyov | — | — |
| Kenny Green | — | 2022 |
Revenue by product and region
Fiscal year ended Dec 31, 2025: $3.85M total revenue
By product
- Industrial application [Member]$2.17M56.3%
- Agriculture [Member]$1.37M35.7%
- Unallocated [Member]$311.00K8.1%
Similar companies
Companies in the same industry as Evogene
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.